Ivonescimab clears half of lung tumours before surgery, but can Akeso prove lasting benefit?
Akeso's ivonescimab delivered 70.1% major pathological response in resectable lung cancer. The Phase 2 trial reveals promise and limitations.
Pharma & Biotech